Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
28 June 2018Website:
http://neurostar.comNext earnings report:
05 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 00:49:57 GMTDividend
Analysts recommendations
Institutional Ownership
STIM Latest News
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast.
Neuronetics, Inc. (NASDAQ:STIM ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity James Beers - William Blair Danny Stauder - JMP Operator Good day and thank you for standing by. Welcome to the Neuronetics Third Quarter 2024 Financial and Operating Results Conference Call.
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024.
Data selected for oral presentation reinforce previous findings on safety and efficacy Data selected for oral presentation reinforce previous findings on safety and efficacy
MALVERN, Pa. and TORONTO , Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Plan of Arrangement"), pursuant to which, subject to the satisfaction or waiver of all applicable conditions precedent, Neuronetics will acquire all of the issued and outstanding common shares of Greenbrook ("Greenbrook Shares") in an all-stock transaction (the "Arrangement").
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies Policy update increases access for millions covered by HCSC BlueCross BlueShield policies
Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression
Upgrades improve communication, streamline data management, and strengthen security Upgrades improve communication, streamline data management, and strengthen security
NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives
- 1(current)
- 2
What type of business is Neuronetics?
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
What sector is Neuronetics in?
Neuronetics is in the Healthcare sector
What industry is Neuronetics in?
Neuronetics is in the Diagnostics & Research industry
What country is Neuronetics from?
Neuronetics is headquartered in United States
When did Neuronetics go public?
Neuronetics initial public offering (IPO) was on 28 June 2018
What is Neuronetics website?
https://neurostar.com
Is Neuronetics in the S&P 500?
No, Neuronetics is not included in the S&P 500 index
Is Neuronetics in the NASDAQ 100?
No, Neuronetics is not included in the NASDAQ 100 index
Is Neuronetics in the Dow Jones?
No, Neuronetics is not included in the Dow Jones index
When was Neuronetics the previous earnings report?
No data
When does Neuronetics earnings report?
The next expected earnings date for Neuronetics is 05 March 2025